Pro Login

Novo Nordisk Shares Drop 14% After Sales Warning for 2026

A stylized illustration of a cylindrical cup with blue arrows and lines indicating a swirling or rotational motion inside the cup.
Published Feb 3, 2026
Share:
A tablet displays a red downward stock chart next to a calendar marked 2026, an injection device, a vial, and financial documents on a desk, reflecting the impact of a sales warning on Novo Nordisk shares.
Summary:
  • Novo Nordisk's U.S. shares fell 14% after the company warned of lower sales and profit growth for 2026.
  • The company anticipates sales and operating profit declines of 5% to 13% at constant exchange rates.
  • In 2025, Novo Nordisk reported a 10% increase in sales and a 6% increase in operating profit.

Sales Warning Affects Stock Performance

Novo Nordisk's shares plummeted on Tuesday, falling as much as 14% after the company announced a decline in sales and profit growth for 2026.

The company pointed to lower prices in the U.S. and the loss of exclusivity for its popular drugs, Wegovy and Ozempic, in several international markets, including China, Brazil, and Canada.

Declining Profit Outlook

For the upcoming year, Novo Nordisk expects sales and operating profits to decline between 5% and 13% at constant exchange rates.

This forecast is significantly worse than what analysts had anticipated. The company is currently facing challenges in its largest market, the U.S., which is impacting its overall performance.

Performance Review for 2025

Despite the ominous outlook for 2026, Novo Nordisk reported a 10% increase in sales and a 6% increase in operating profit for 2025.

In the fourth quarter, the company saw net sales total 79.1 billion Danish kroner, which is equivalent to about $12.5 billion, slightly exceeding the analysts' expectations of 77.8 billion kroner.

Key Drug Sales Figures

In the fourth quarter, Novo Nordisk's best-selling drug, Ozempic, generated sales of 31.8 billion kroner, marking a 1% increase compared to the same period last year.

Additionally, Wegovy sales reached 21.9 billion kroner, reflecting a 17% increase year-over-year.

Market Competition and Future Plans

With increasing competition from Eli Lilly's weight-loss drug, tirzepatide, Novo Nordisk is striving to regain market share in the U.S. market.

The company is optimistic about launching Wegovy in more countries in 2026 and introducing a higher 7.2 mg dose in several markets.

What’s Next for Novo Nordisk?

Moving forward, Novo Nordisk is focusing on the U.S. launch of the oral version of Wegovy. CEO Mike Doustdar expressed confidence in the drug's potential to drive volume growth in the coming years, despite the current pricing pressures and competition.

Investors remain cautious, however, as they await updates on Novo’s strategy to navigate the shifting market dynamics.

Disclosure

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

April 13, 2026
What Is Free Cash Flow? How To Find It & Why It's Important
  • Free cash flow is the cash a company has left after paying its bills and putting money back into the business.
  • Investors use free cash flow to figure out what a company is really worth - and if the stock is a good deal.
  • You can find free cash flow on a company's cash flow report, one of three key reports every public company files.
Read More
April 13, 2026
Non Taxable Income: What It Is and Why Investors Care

Non taxable income is money you earn that the IRS does not tax - like Roth IRA cash, muni bond interest, and certain investment gains. The U.S. tax code taxes workers, investors, and business owners at very different rates. Tools like Roth accounts, muni bonds, and real estate write-offs can help you keep more of what you earn.

Read More
April 11, 2026
Nasdaq Index Fund: A Beginner's Guide to Investing in the Nasdaq 100
  • A Nasdaq index fund lets you invest in the 100 biggest non-bank companies on the stock market all at once.
  • You can access the Nasdaq through index funds, mutual funds, or ETFs like QQQ - each with its own fees, trading rules, and style.
  • Picking the right Nasdaq index fund comes down to three things: who runs it, what is in it, and what it costs.
Read More
April 11, 2026
What Is Wealth? It's Not What Most People Think
  • Wealth is about owning assets that grow and pay you - not just earning a high salary.
  • In a capitalist system, there are two ways to get paid: from your labor and from your capital.
  • Building wealth takes a shift in mindset, a money system, and the habit of investing before you spend.
Read More
April 10, 2026
Micron Stock: The AI Memory Play Most Investors Are Missing
  • Micron (MU) is the only U.S. company that makes HBM chips - the short-term memory layer that AI systems need to run.
  • By early 2026, data centers were using about 70% of all memory chips made in the world, creating an 18-month backlog for new orders.
  • Micron's DRAM - or short-term memory chip - revenue jumped 69% year over year, and the company shifted away from consumer products to focus almost entirely on AI.
Read More
April 10, 2026
What Is Working Capital? What Investors Need To Know
  • Working capital is current assets minus current liabilities - it shows if a business can pay its short-term bills.
  • You find it on a company's balance sheet inside its 10-K report.
  • Changes in working capital show up on the cash flow statement and affect how much cash a business really makes.
Read More
April 9, 2026
What Is a Meme Stock? A Simple Guide for New Investors

You've probably heard the term "meme stock" thrown around on […]

Read More
April 9, 2026
Enterprise Value Formula: What It Is and How to Calculate It
  • Enterprise value (EV) shows what a company is really worth - debt and cash included - not just its stock price
  • The enterprise value formula is: Market Cap + Total Debt - Cash and Cash Equivalents
  • Investors use EV with metrics like EBITDA to compare stocks more fairly than market cap alone
Read More
April 8, 2026
Return on Equity: What It Is and How to Use It
  • Return on equity (ROE) measures how much profit a company earns for every dollar of shareholder equity
  • The formula is simple: net income divided by shareholder equity
  • A higher ROE can signal a company that is good at turning investor money into profit - but it is not the full picture
Read More
April 4, 2026
Personal Finance Books That Actually Teach You to Build Wealth

Most investors grow up hearing the same financial advice. Study […]

Read More
1 2 3 17
Share via
Copy link